Reply to: “Serotype transition in invasive pneumococcal infection in postvaccine era”  by Shen, Ching-Fen et al.
Journal of the Formosan Medical Association (2015) 114, 787e788Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jfma-onl ine.comLETTER TO THE EDITORReply to: “Serotype transition in invasive
pneumococcal infection in postvaccine era”Table 1 Demographic data and clinical outcomes of hos-
pitalized children with invasive pneumococcal disease from
1998 to 2010 according to PCV7 and non-PCV7 serotypes.
Basic information PCV7
serotypes
(n Z 75)
Non-PCV7
serotypes
(n Z 30)
p
Age (y) 3.6  2.8 3.9  2.2 0.199
Male/female ratio 1.2 1.5 0.620
Underlying disease 18 (24.0) 6 (20) 0.661
Previous
pneumococcal
vaccinationa
2/72 (2.8) 1/29 (3.4) >0.99
Duration of
hospitalization (d)
15.3  10.7 16.2  8.5 0.230
Total febrile d 7.0  6.0 9.6  5.5 0.015
Requirement
for ICU stay
29/70 (41.4) 20/29 (69.0) 0.013
Duration of
ICU stay (d)
11.3  6.7 11.5  6.3 0.894
Hemodynamic instability 14/72 (19.4) 7/29 (24.1) 0.601
Respiratory failure 13/72 (18.1) 6/29 (20.7) 0.760
Complicated pneumonia 16/29 (55.2) 15/19 (78.9) 0.096
Mortality 4 (5.3) 3 (10.0) >0.99
Data are presented as mean  SD or n/N (%).To the Editor,
We thank Dr W.C. Huang for the correspondence1 on
changing serotype epidemiology of invasive pneumococcal
disease (IPD) of our study.2 With regard to the question
about the underlying diseases of patients in 7-valent con-
jugate pneumococcal vaccine (PCV7) and non-PCV7 sero-
type groups, we had analyzed the immune status of these
patients. Among patients with underlying diseases, hema-
tological malignancy was the most common disease with
impaired immune function. However, the patients with
hematological diseases were not significantly different be-
tween the PCV7 group and non-PCV7 group (12% vs. 10%,
p > 0.05). These patients were further analyzed by severe
neutropenia (absolute neutrophil counts < 500 cell/mm3)
at the onset of IPD. There was still no significant difference
by severe neutropenia between the two groups (4% in the
PCV7 group vs. 6.7% in the non-PCV7 group, p > 0.05).
Nephrotic syndrome was the second most common disease
that might compromise the host immune system, leading to
susceptibility to IPD. Among patients with nephrotic syn-
drome and IPD, all of them had hypoalbuminemia. The
cases of nephrotic syndrome also did not differ significantly
between the two groups (5.3% vs. 6.7%, p > 0.05). As to the
comments on previous 23-valent polysaccharide vaccina-
tion, we have addressed these in detail in the text. Two
cases developed breakthrough infections (serotypes 6B and
14), and another had serotype 23A/B pneumococcal infec-
tion within the following 2 years after vaccination. None of
them had comorbidity. All three cases developed uncom-
plicated lobar pneumonia and had concurrent bacteremia.
The sample size of vaccine breakthrough infections in the
current study was too small to conclude that previous
vaccination could convert to protection and lessen disease
severity. However, the disease severity was more closely
related to the host’s comorbidity and the pneumococcal
serotypes with regard to previous vaccination.3 As regardsConflicts of interest: The authors have no conflicts of interest
relevant to this article.
http://dx.doi.org/10.1016/j.jfma.2015.03.016
0929-6646/Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medicathe number of enrolled cases in Table 1, there were six
patients (5 in the PCV group and 1 in the non-PCV7 group)
who were not hospitalized. We excluded these cases from
the item, the percentage of requirement of ICU stay. In
summary, our study raised concerns about non-PCV7 sero-
type infection and its high association with complicated
pneumonia. Continuous monitoring of the changing sero-
type of IPD, as well as the clinical manifestations is needed,
even in the era of universal 13-valent conjugate pneumo-
coccal vaccination.ICU Z intensive care unit; PCV7 Z 7-valent conjugate pneu-
mococcal vaccine; SD Z standard deviation.
a 23-valent polysaccharide pneumococcal vaccine (PPV23).
l Association. All rights reserved.
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